KeyCorp Estimates Exagen's FY2026 Earnings (NASDAQ:XGN)

Key Points

• KeyCorp has issued a FY2026 earnings forecast for Exagen, projecting an earnings per share of ($0.31), while the current consensus estimate is ($0.88) per share.
• Exagen recently reported quarterly earnings of ($0.18) EPS, meeting analysts' expectations, and generated $17.20 million in revenue for the quarter.
• A majority of analysts have a buy rating on Exagen, with the stock's average price target set at $10.50.

Exagen Inc. (NASDAQ:XGN - Free Report) - KeyCorp issued their FY2026 earnings per share (EPS) estimates for shares of Exagen in a report issued on Tuesday, July 29th. KeyCorp analyst P. Knight expects that the company will post earnings per share of ($0.31) for the year. KeyCorp has a "Overweight" rating and a $12.00 price objective on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

Exagen (NASDAQ:XGN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.18). Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%. The business had revenue of $17.20 million during the quarter, compared to analyst estimates of $16.25 million.

A number of other equities analysts also recently issued reports on the company. Canaccord Genuity Group upped their price target on Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday. Craig Hallum started coverage on shares of Exagen in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price target on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $10.00 price target on shares of Exagen in a report on Wednesday. UBS Group reiterated an "overweight" rating on shares of Exagen in a report on Thursday, May 15th. Finally, BTIG Research reissued a "buy" rating on shares of Exagen in a research report on Wednesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $11.25.

Exagen Trading Up 2.7%

XGN traded up $0.23 on Thursday, hitting $8.63. The company had a trading volume of 282,684 shares, compared to its average volume of 428,131. The business's fifty day simple moving average is $7.19 and its 200 day simple moving average is $5.43. The company has a quick ratio of 2.32, a current ratio of 4.95 and a debt-to-equity ratio of 1.06. Exagen has a 12-month low of $1.78 and a 12-month high of $9.10. The company has a market cap of $189.86 million, a PE ratio of -9.70 and a beta of 1.61.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC purchased a new position in Exagen in the first quarter valued at about $25,000. Corient Private Wealth LLC acquired a new stake in shares of Exagen in the fourth quarter valued at approximately $45,000. Virtu Financial LLC acquired a new stake in shares of Exagen in the fourth quarter valued at approximately $46,000. Marshall Wace LLP acquired a new stake in shares of Exagen in the fourth quarter valued at approximately $66,000. Finally, Northern Trust Corp grew its position in shares of Exagen by 16.7% in the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock valued at $75,000 after purchasing an additional 2,630 shares during the last quarter. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).